Subject index of volume 20

Adriamycin 122
Alveolar macrophages 158
Antibody
– monoclonal 75, 85, 137
Antigen
– p50 23
– cell shedding 129
– differentiation 75
Anti-metastatic activity 18

BCG
– intralesional treatment 223
Bladder carcinoma 23, 236

Cattle
– orbital carcinoma 223
Clonogenic assay 55
Colon carcinoma 129
Corynebacterium parvum 117, 214
Cyclophosphamide 175

Difluoromethylornithine 214

Hypersensitivity
– delayed type 179
Hypertensive rats 103

Immune-complexes 80, 91
Immunocompetence 38
Immunopotentiator 43, 109
Immunostimulation 61
Immunosuppression 167
Immunotherapy
– adoptive 198
– specific adjuvant 231
Interferon 189
– gamma 151
– recombinant gamma 193

Kupffer cells 117

Lactobacillus casei 18, 109, 117
Leukemia 75, 80, 91
Leukocyte
– lung 11
Lung
– cancer 43, 158
– leukocyte 11
– Lewis lung carcinoma 18
– squamous lung carcinoma 231
Lymphocyte
– B 23
– MLR 209
– MLTC 29
– murine stimulation 209
– tumor associated 29
Lymphokine 151
Lymphoma 75, 80, 198

Macrophage 6, 69, 97, 145, 158, 167, 205
Mammary carcinoma 175
Mammary gland 219
Melanoma 11, 214
Melphalan 61, 209
Metastasis 103
Monoclonal antibody 75, 85, 137
Monocyte 43, 151
MTP-PE 11
Muramyl dipeptide 183

Natural defense 103
Neocarcinostatin 85
NK cells 122, 189, 236

Orbital carcinoma
– cattle 223

Plasmacytoma 47
Poly I:Poly C 236
Pyrancopolymer 69

Suppressor cells 97

T cell
– depression 103
– helper 183
– suppressor 209
– T-T cell interaction 183
Thymosin α1 189
Tumor
– associated lymphocytes 29
– immunity 219
– MAT 13762 175
– MLTC 29
– modified tumor cells 179
– necrosis factor 1, 6
– resistance 122
– stem cells 55
– vaccine 69

Founding Editor
G. Mathé

Cancer Immunology Immunotherapy

Other Biological Response Modifications

Volume 20 1985

Editors in Chief

R. W. Baldwin **E. Mihich**

Editorial Board

R. Bast Durham
T. Boon Brussels
E. C. Borden Madison
T. Carey Ann Arbor
M. Cheever Seattle
G. A. Currie Oxted, Surrey
W. Den Otter Utrecht
J. E. de Vries Amsterdam
S. Dray Chicago
S. Eccles Sutton, Surrey
I. Fidler Houston
A. Goldstein Washington
E. Grimm Bethesda
K. Hellström Seattle
E. Klein Stockholm
H. Kobayashi Sapporo
M. Mastrangelo Philadelphia
W. H. McBride Edinburgh
M. Micksche Vienna
P. Minden La Jolla
M. Mitchell Los Angeles
R. J. North Saranac Lake
H. Ozer Buffalo
G. Parmiani Milano
H. M. Pinedo Amsterdam
P. Reizenstein Stockholm
P. Rümke Amsterdam
V. Schirrmacher Heidelberg
D. Scott Rochester
F. Spreafico Milan
F. Vánky Stockholm
B. Vose Cheshire
Y. Yagi Kamakura City
K. Yamamoto Kanazawa
Y. Yamamura Osaka

Springer International

Cancer Immunology Immunotherapy
Other Biological Response Modifications

This journal was founded in 1976. Founding editor: G. Mathé
Editors: R. W. Baldwin, E. Mihich
Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e. g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US $ 0.20 per page, or a minimum of US $ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Other regulations

Authors publishing in this journal can, under certain conditions, benefit from library and photocopy fees collected by VG WORT. Authors of German nationality, and those resident in the Federal Republic of Germany or Berlin (West), as well as citizens of Austria, Switzerland and member countries of the European Community, may apply to Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, for detailed information.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß

© Springer-Verlag Berlin Heidelberg 1985

Contents of volume 20

Abrams PG, see Foon KA, et al. 193
Adler R, see Takita H, et al. 231
Azuma I, see Matsuzaki T, et al. 18

Bagasra O, Berman W, Hashemi S, Howeedy A, Kushner H: In vitro cloning of tumor stem cells in semi-solid media containing agar and agarose 55
Bauguess CT, see Gangemi JD, et al. 158
Ben-Aissa H, see Paulie S, et al. 23
Ben-Efraim S, see Bocian RC, et al. 61
Ben-Efraim S, see Ophir R, et al. 209
Benoist H, Madoulet C, Jardillier J-C, Desplaces A: Adriamycin induced resistance of sensitive K-562 cells to natural killer lymphocyte attack 122
Berman W, see Bagasra O, et al. 55
Bhayana J, see Takita H, et al. 231
Bocian RC, Dray S, Ben-Efraim S, Mokyr MB: Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the speen of mice bearing a large metastatic MOPC-315 tumor 61
Bonaventure J, Nigam VN, Brailovsky CA: Modulation of the immunosuppressive effects of splenic macrophages in Fischer rats bearing adenocarcinoma 13762 167
Bowlin TL, Rosenberger AL, Sunkara PS: The effect of combination treatment with alphadifluoromethylornithine and *Corynebacterium parvum* on B16 melanoma growth and tumoricidal effector cell generation in vivo 214
Brailovsky CA, see Bonaventure J, et al. 167
Braun DG, see Brownbill AF, et al. 11
Brownbill AF, Braun DG, Dukor P, Schumann G: Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide 11
Brüggen J, see Lüders G, et al. 85

Colombo MP, Parenza M, Parmiani G: Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: Characterization of the effector population and evidence for the role of the host's non-T cells 198
Croce MV, Fejes M, Riera N, Minoldo DA, Segal-Eiras A: Clinical importance of circulating immune complexes in human acute lymphoblastic leukemia 91

Desplaces A, see Benoist H, et al. 122
Doljanski F, see Markson Y, et al. 129
Dray S, see Bocian RC, et al. 61
Drexler HG, Gignac S, Misra B, Skowron L, Menon M, Minowada J: High concordance between marker profiles of 22 human leukemia-lymphoma cell lines tested with the same monoclonal antibodies before and during the second international workshop on human differentiation antigens 75
Dukor P, see Brownbill AF, et al. 11

Eblin-Henriksson B, see Paulie S, et al. 23
Ejiri T, see Nakata Y, et al. 43

Favalli C, Jezzi T, Mastino A, Rinaldi-Garaci C, Riccardi C, Garaci E: Modulation of natural killer activity by thymosin alpha 1 and interferon 189
Fechter C, see Gangemi JD, et al. 158
Fejes M, see Croce MV, et al. 91
Fidler IJ, see Kleinerman ES, et al. 151
Foon KA, Sherwin SA, Abrams PG, Stevenson HC, Holmes P, Maluish AE, Oldham RK, Herberman RB: A phase I trial of recombinant gamma interferon in patients with cancer 193
Fujiwara, see Hamaoka T, et al. 183

Gangemi JD, Olsen GN, Fechter C, Hightower JA, Bauguess CT, Krech L: Phagocytic activity of alveolar macrophages in patients with bronchogenic carcinoma 158
Garaci E, see Favalli C, et al. 189
Gignac S, see Drexler HG, et al. 75
Gopal R, see Patel GV, et al. 80

Hamada JT, see Koga Y, et al. 103
Hamaoka T, Takai Y, Kosugi A, Mizushima Y, Shima J, Kusama T, Fujiwara H: The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity 183
Haranaka K, Satomi N, Sakurai A, Haranaka R, Okada N, Kobayashi M: Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs 1
Haranaka K, see Sakurai A, et al. 6
Haranaka K, see Haranaka K, et al. 1
Hart G, see Misdorp W, et al. 223
Hart T, Jr, see Takita H, et al. 231
Hashemi S, see Bagasra O, et al. 55
Hashimoto S, Seyama Y, Yokokura T, Mutai M: Cytotoxic factor production by Kupffer cells elicited with *Lactobacillus casei* and *Corynebacterium parvum* 117
Hayashi S, see Shindo H, et al. 145
Heppner GH, see Wei W-Z, et al. 137
Herberman RB, see Foon KA, et al. 193
Hightower JA, see Gangemi JD, et al. 158
Hollinshead A, see Takita H, et al. 231
Holmes P, see Foon KA, et al. 193
Hoon DSB, Ramshaw IA: Chemoimmunotherapeutic effect of cyclophosphamide on the highly metastatic MAT 13762 tumor 175
Howeedy A, see Bagasra O, et al. 55
Hyde AM, Stagg RB, McEachron R, Nutter RL: Effects of the removal of adherent and phagocytic cells on the spleen cell lymphoproliferative response of tumor-bearing mice 97

Jardillier J-C, see Benoist H, et al. 122
Jezzi T, see Favalli C, et al. 189
de Jong WH, see Misdorp W, et al. 223

Kataoka M, see Nakata Y, et al. 43
Kataoka T, Oh-hashi F: Non-cytotoxic activity of pyran copolymer-induced macrophages associated with potentiation of tumour vaccine in recipient mice 69
Keisari Y, see Marcovitch S, et al. 205
Kimura I, see Nakata Y, et al. 43
Kishi T, see Nakata Y, et al. 43
Kishimoto S, see Shindo H, et al. 145
Klein WR, see Misdorp W, et al. 223
Kleinerman ES, Wiltrout RH, Zicht R, Fidler IJ: Human lymphokine preparations which generate tumoricidal properties of human monocytes in vitro may be distinct from gamma interferon 151
Kobayashi H, see Koga Y, et al. 103
Kobayashi M, see Haranaka K, et al. 1
Koga Y, Hamada J-T, Takeichi N, Nakane A, Minagawa T, Kobayashi H: Activation of natural resistance against lung metastasis of an adenocarcinoma in T-cell depressed spontaneously hypertensive rats by infection with *Listeria monocytogenes* 103
Köhnlein W, see Lüders G, et al. 85
Koho H, see Paulie S, et al. 23
Koide Y, see Yasutake N, et al. 109
Kosugi A, see Hamaoka T, et al. 183
Kovařík J, see Munzarová, et al. 179
Krech L, see Gangemi JD, et al. 158
Kupfer B, see Moroz C, et al. 236
Kusama T, see Hamaoka T, et al. 183
Kushner H, see Bagasra O, et al. 55

Lehto I, see Nordman E. et al. 38
Lindner A, see Moroz C, et al. 236
Lüders G, Köhnlein W, Sorg C, Brüggen J: Selective toxicity of neocarzinostatin-monoclonal antibody conjugates to the antigen-bearing human melanoma cell line in vitro 85

Madoulet C, see Benoist, et al. 122
Maluish AE, see Foon KA, et al. 193
Many M, see Moroz C, et al. 236
Marcovitch S, Keisari Y: The synergistic tumoricidal activity of anticancer drugs and oxidative burst-triggered macrophages 205
Markson Y, Weiss DW, Weiss O, Doljanski F: Presence of normal human cell surface antigens in plasma of athymic mice bearing a human colon carcinoma and in normal human plasma 129
Massey RJ, see Wei W-Z, et al. 137
Mastino A, see Favalli C, et al. 189
Masuno T, see Shindo H, et al. 145
Matsuzaki T, Yokokura T, Azuma I: Anti-tumor activity of Lactobacilus casei on Lewis lung carcinoma and line-10 hepatoma in syngeneic mice and guinea pigs 18
McEachron R, see Hyde AM, et al. 97
Mellstedt H, see Paulie S, et al. 23
Menon M, see Drexler HG, et al. 75
Miller FR: Concomitant tumor immunity in the mammary gland- 219
Minagawa T, see Koga Y, et al. 103
Minoldo DA, see Croce MV, et al. 91
Minowada J, see Drexler HG, et al. 75
Misdorp W, Klein WR, Ruitenberg EJ, Hart G, de Jong WH, Steerenberg PA: Clinicopathological aspects of immunotherapy by intralesional injection of BCG cell walls or live BCG in bovine ocular squamous cell carcinoma 223
Misra B, see Drexler HG, et al. 75
Mizushima Y, see Hamaoka T, et al. 183
Mokyr MB, see Bocian RC, et al. 61
Moore M, see Uchida A, et al. 29
Moroz C, Kupfer B, Lindner A, Many M: Treatment of patients with transitional cell carcinoma of the urinary bladder with intravesical poly I: Poly C effects on natural killer function 236
Moskowitz R, see Takita H, et al. 231
Munzarová M, Zemanová D, Kovařík J, Rejthar A, Pačovský Z: Skin tests with autologous cholesteryl hemisuccinate treated tumour cells in cancer patients 179
Mutai M, see Yasutake N, et al. 109
Mutai M, see Hashimoto S, et al. 117

Nadkarni JJ, see Patel GV, et al. 80
Nakane A, see Koga Y, et al. 103
Nakata Y, Yamashita J, Kishi T, Kataoka M, Ejiri T, Ohnoshi T, Kimura I: Decreased monocyte-mediated cytostasis of human cancer cell in patients with lung cancer 43
Nigam VN, see Bonaventure J, et al. 167
Nordman E, Lehto I, Toivanen A: Immune functions and the prognosis of patients with solid tumours 38
Nutter RL, see Hyde AM, et al. 97

Ogura T, see Shindo H, et al. 145
Oh-hashi F, see Kataoka T, et al. 69
Ohnoshi T, see Nakata Y, et al. 43
Ohwaki M, see Yasutake, et al. 109
Okada N, see Haranaka K, et al. 1
Oldham RK, see Foon KA, et al. 193
Olsen GN, see Gangemi JD, et al. 158
Ophir R, Ben-Efraim S: Effect of melphalan in vitro on induction of murine suppressor T cells by ConA 209

Pačovský Z, see Munzarová M, et al. 179
Parenza M, see Colombo MP, et al. 198
Parmiani G, see Colombo MP, et al. 198
Patel, GV, Gopal R, Nadkarni JJ: Evaluation of circulating immune complexes in lymphomas and leukemias using two different assays 80
Paulie S, Eblin-Henriksson B, Mellstedt H, Koho H, Ben-Aissa H, Perlmann P: A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes 23
Perlmann P, see Paulie S, et al. 23
Phillips-Quagliata, see Walker MC, et al. 47

Ramshaw IA, see Hoon DSB, et al. 175
Ramundo M, see Takita H, et al. 231
Rao U, see Takita H, et al. 231
Rejthar A, see Munzarová M, et al. 179
Riccardi C, see Favalli C, et al. 189
Riera N, see Croce MV, et al. 91
Rinaldi-Garaci C, see Favalli C, et al. 189
Rosenberger AL, see Bowlin TL, et al. 214
Ruitenberg EJ, see Misdorp W, et al. 223

Sakurai A, see Haranaka K, et al. 1
Sakurai A, Satomi N, Haranaka K: Tumour necrosis factor and the lysosomal enzymes of macrophages or macrophage-like cell line 6
Satomi N, see Haranaka K, et al. 1
Satomi N, see Sakurai A, et al. 6
Schumann G, see Brownbill AF, et al. 11
Segal-Eiras A, see Croce MV, et al. 91
Seyama Y, see Hashimoto S, et al. 117
Sherwin SA, see Foon KA, et al. 193
Shima J, see Hamaoka T, et al. 183
Shindo H, Ogura T, Masuno T, Hayashi S, Kishimoto S: Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice 145
Skowron L, see Drexler HG, et al. 75
Sorg C, see Lüders G, et al. 85
Stagg RB, see Hyde AM, et al. 97
Steerenberg PA, see Misdorp W, et al. 223
Stevenson HCV, see Foon KA, et al. 193
Sunkara PS, see Bowlin TL, et al. 214

Takai Y, see Hamaoka T, et al. 183
Takeichi N, see Koga Y, et al. 103
Takita H, Hollinshead A, Hart T, Jr., Bhayana J, Adler R, Rao U, Moskowitz R, Ramundo M: Adjuvant specific immunotherapy of resectable squamous cell lung carcinoma. Analysis at the eighth year 231
Toivanen A, see Nordman E, et al. 38

Uchida A, Moore M: Lysis of fresh human tumor cells by autologous tumour-associated lymphocytes: Two distinct types of autologous tumour killer cells induced by co-culture with autologous tumour 29

Walker MC, Phillips-Quagliata JM: Comparison of patterns of hybrid resistance to the BALB/c plasmacytomas LPC-1 and MPC-11 47
Wei W-Z, Massey RJ, Heppner GH: A 3-dimensional tumor growth inhibition assay for testing monoclonal antibody cytotoxicity- 137
Weiss DW, see Markson Y, et al. 129
Weiss O, see Markson Y, et al. 129
Wiltrout RH, see Kleinerman ES, et al. 151

Yamashita J, see Nakata Y, et al. 43
Yasutake N, Ohwaki M, Mutai M, Koide Y, Yoshida T: Anti-tumor effect of humoral and cellular immunities mediated by a bacterial immunopotentiator, *Lactobacillus casei*, in mice 109
Yokokura T, see Matsuzaki T, et al. 18
Yokokura T, see Hashimoto S, et al. 117
Yoshida T, see Yasutake, N, et al. 109

Zemanová D, see Munzarová M, et al. 179
Zicht R, see Kleinerman ES, et al. 151